이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

계란과 영양 강화 계란의 정기적인 섭취가 싱가포르 개인의 습진 상태에 미치는 영향

2026년 11월 10일 업데이트: Jung Eun Kim, National University of Singapore

습진이 있는 싱가포르 개인의 습진 상태에 대한 계란 및 영양 강화 계란의 정기적인 섭취가 미치는 영향

The study aims to assess the effects of daily consumption of nutrients-fortified eggs on eczema condition in Singapore individuals with eczema. The investigators hypothesize that egg consumption will improve eczema condition and nutrients fortified egg consumption will improve further improvements when compared to standard egg consumption in individuals with eczema

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

This is a double-blind, randomized, parallel study and all subjects will complete a 12-week study period. Subjects will be tasked to consume nutrients-fortified eggs and regular eggs daily for 12 weeks. After which, subjects are assessed for changes in carotenoid status, antioxidant and anti-inflammatory biomarkers, skin and eye health measurements, and other biomarkers of health.

연구 유형

중재적

등록 (실제)

43

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Singapore
      • Singapore, Singapore, 싱가포르, 117550
        • Department of Food Science and Techonology, Block S13

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

21년 (성인)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. English-literate and able to give informed consent in English
  2. Male and female participants, aged between 21 and 59 inclusive
  3. Healthy individuals with no underlying condition or on regular medication
  4. BMI between 18.5-25 kg/m2
  5. Mild to moderate severity of eczema, which will also be determined using our questionnaires during the screening visit

Exclusion Criteria:

  1. Significant change in body weight (3 kg or more) in the past 3 months
  2. Significant exercise pattern over the past 3 months defined as high-intensity exercise of more than 3 hours per week
  3. Known food allergy to eggs
  4. Taking dietary supplements which may impact the study results
  5. Having gastrointestinal disorders not suitable for the study
  6. Current smokers
  7. Consumes more than 2 alcoholic drinks per day i.e. one drink is defined as either 150ml of wine, 340ml of beer/cider, or 45ml of distilled spirit
  8. Taking lipid-lowering and blood pressure-controlling medications for less than 3 years
  9. Pregnant or lactating women, or planning to conceive in the next 6 months
  10. Unwilling to stop the medication of eczema during the study, either topical creams or oral medications
  11. Hierarchical link (professional and familial ties) with the research team members
  12. Participating in another clinical study
  13. Having blindness in one eye or more, eye diseases, retinal/lens/optical nerve surgery, or other eye conditions that may impact the study results
  14. Low-quality macular pigment optical density results were determined during the screening visit.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Regular egg with habitual diet

Each subject will be provide one-on-one dietary counselling and written instructions for each subject will be provided by a research dietitian and trained research staff.Subjects will also be provided with 2 regular egg/day for 12 weeks.

Consumption of regular egg with habitual diet

실험적: Nutrient-fortified egg with habitual diet

Each subject will be provide one-on-one dietary counselling and written instructions for each subject will be provided by a research dietitian and trained research staff.Subjects will also be provided with 2 nutrient-fortified egg/day for 12 weeks.

Consumption of nutrient-fortified eggs with habitual diet

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Skin questionnaires - SCORing Atopic Dermatitis (SCORAD) Index
기간: Week 0, week 3, week 6, week 9, week 12

SCORing Atopic Dermatitis (SCORAD) Index is a clinical tool used to assess the severity of atopic dermatitis (AD), also known as eczema. This index can estimate participants' body surface area affected by burns (extent - A: percentage of body surface area affected), Intensity (B: clinical signs are assessed and scored on a scale from 0 (absent) to 3 (severe)), Subjective Symptoms (C: itch, sleep disturbance are evaluated based on the participants' report over the past three days, each scored on a scale from 0 (no symptom) to 10(severe symptom)).

The SCORAD index is calculated using the following formula:

SCORAD=A/5+7B/2+C

Interpretation Mild atopic dermatitis: SCORAD < 25 Moderate atopic dermatitis: SCORAD 25-50 Severe atopic dermatitis: SCORAD > 50

Week 0, week 3, week 6, week 9, week 12
Skin questionnaires - Eczema Area and Severity Index (EASI) scoring system
기간: Week 0, week 3, week 6, week 9, week 12

EASI evaluates the extent and severity of eczema in four body regions: the head and neck, the trunk, the upper limbs, and the lower limbs.

The EASI score ranges from 0 to 72, with higher scores indicating more severe eczema:

0: No eczema 1-7: Mild eczema 8-21: Moderate eczema 22-50: Severe eczema 51-72: Very severe eczema

Week 0, week 3, week 6, week 9, week 12
Skin questionnaires - Dermatology life quality index (DLQI)
기간: Week 0, week 3, week 6, week 9, week 12

DLQI is a dermatology-specific instrument used to measure the impact of skin diseases on patients' quality of life. Which assessed disease impact, monitor treatment effectiveness, guide clinical decision-making.

Interpretation of Scores:

0-1: No effect on patient's life 2-5: Small effect on patient's life 6-10: Moderate effect on patient's life 11-20: Very large effect on patient's life 21-30: Extremely large effect on patient's life

Week 0, week 3, week 6, week 9, week 12
Skin measurement - eczema related
기간: Week 0, week 3, week 6, week 9, week 12

Skin hydration - units arbitrary Corneometer®. Transepidermal water loss - units gram/hour. Sebum level - unit µg/cm2. Skin pH level - skin pH meter. Skin tape stripping: stratum corneum components assessed by immune dot blots

Week 0, week 3, week 6, week 9, week 12
Skin carotenoids status
기간: Week 0, week 3, week 6, week 9, week 12

Skin carotenoids concentration can be measured by Resonance Raman Spectroscopy, unit is skin carotenoid score, higher score means optimal, lower score means poor condition of skin carotenoids.

Week 0, week 3, week 6, week 9, week 12
Blood carotenoids levels
기간: Week 0, week 6, week 12

Blood carotenoids levels can be measured by High-Performance Liquid Chromatography, unit is μmol/L.

Week 0, week 6, week 12

2차 결과 측정

결과 측정
측정값 설명
기간
Eye health - Macular Pigment Optical Density
기간: Week 0, week 3, week 6, week 9, week 12

A measurement of macular pigment of the eye using a heterochromatic flicker photometry device. The measurements are in arbitrary units.

Week 0, week 3, week 6, week 9, week 12
Eye health - Visual acuity
기간: Week 0, week 3, week 6, week 9, week 12

Participants will read out letters on a ETDRS LogMAR chart at a fixed distance where letters becomes smaller as it goes down the chart. Tests results will be recorded in number of letters read, where the more letters the better the outcome.

Week 0, week 3, week 6, week 9, week 12
Eye health - Photostress recovery time
기간: Week 0, week 3, week 6, week 9, week 12

An ophthalmoscope will be used to shine a light into the participants eye for 10 seconds, and participants will be required to read letters off a chart the moment their vision returns to normal. The faster the recovery time, the better the outcome. Units will be in seconds

Week 0, week 3, week 6, week 9, week 12
Visual function questionnaire 25
기간: Week 0, week 3, week 6, week 9, week 12

A questionnaire to for participants to self-evaluate their perception of their current eye health based on general vision, ocular pain, near activities, distance activities, vision specific functions, driving, color vision and peripheral vision. The best possible score is 100 and worst possible score is 0.

Week 0, week 3, week 6, week 9, week 12
Concentration of tumour necrosis factor-α
기간: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. Tumor necrosis factor-α results will be presented in ng/L according to the commercially available enzyme-linked immunosorbent assay kits.

Week 0, week 6, week 12
Concentration of interleukin-6
기간: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. Interleukin-6 results will be presented in ng/L according to the commercially available enzyme-linked immunosorbent assay kits.

Week 0, week 6, week 12
Concentration of high-sensitivity C-reactive protein
기간: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. High-sensitivity C-reactive protein results will be obtained and presented in mg/L by commercial lab testing.

Week 0, week 6, week 12
Concentration of fasting blood glucose
기간: Week 0, week 6, week 12

Fasting blood glucose will be measured using commercial lab testing using participants' blood, units will be in mmol/L.

Week 0, week 6, week 12
Concentration of malondialdehyde
기간: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. Analyses of malondialdehyde using commercially available enzyme-linked immunosorbent assay kits. Units for malondialdehyde will be in ng/L according to assay kit instructions.

Week 0, week 6, week 12
Concentration of 8-isoprostaglandin-F2α
기간: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. Analyses of 8-isoprostaglandin-F2α using commercially available enzyme-linked immunosorbent assay kits. Units for 8-isoprostaglandin-F2α will be in µmol/L according to assay kit instructions.

Week 0, week 6, week 12
Concentration of insulin
기간: Week 0, week 6, week 12

Fasting blood insulin will be measured using commercial lab testing using participants' blood, units in μU/L.

Week 0, week 6, week 12
Percentage of glycated hemoglobin
기간: Week 0, week 6, week 12

Glycated hemoglobin will be measured using commercial lab testing from participant's blood, units in percent.

Week 0, week 6, week 12
Skin advanced glycation end products levels
기간: Week 0, week 3, week 6, week 9, week 12

Measurement of skin advanced glycation end products level using a skin autofluorescence device, where participants wlll be instructed to place their forearm over the device and a light will be shone and a reading can be captured by detecting fluorescence. The results will be presented as arbitrary units.

Week 0, week 3, week 6, week 9, week 12
Blood advanced glycation end products levels
기간: Week 0, week 3, week 6, week 9, week 12

Participants will have their blood drawn by medical professionals at the Occupational Health Clinic. The blood will be processed and stored. Measurements will be done using ultra-performance liquid chromatography coupled with mass spectrometry techniques to determine the levels of advanced glycation end products. Units will be in μg/mL.

Week 0, week 3, week 6, week 9, week 12

기타 결과 측정

결과 측정
측정값 설명
기간
Dietary assessment
기간: Week 0, week 3, week 6, week 9, week 12

3-day food record will be used to assess participants' dietary intake for two weekdays and one weekend day before each clinical visit.

Week 0, week 3, week 6, week 9, week 12
Measurement of height
기간: Week 0, week 3, week 6, week 9, week 12

Height will be measured using height-weight scale and units will be in cm.

Week 0, week 3, week 6, week 9, week 12
Measurement of blood pressure
기간: Week 0, week 3, week 6, week 9, week 12

A blood pressure monitoring device available commercially will be used be to measure their systolic and diastolic blood pressure. Unit is mmHg.

Week 0, week 3, week 6, week 9, week 12
Measurement of weight
기간: Week 0, week 3, week 6, week 9, week 12

Weight will be measured using height-weight scale and units will be in kg.

Week 0, week 3, week 6, week 9, week 12
Measurement of waist circumference
기간: Week 0, week 3, week 6, week 9, week 12

Waist circumference will be measured using a measuring tape by a trained personnel, units in cm.

Week 0, week 3, week 6, week 9, week 12

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Jung Eun Kim, PhD, RD, National University of Singapore

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 7월 17일

기본 완료 (실제)

2025년 10월 27일

연구 완료 (실제)

2025년 12월 1일

연구 등록 날짜

최초 제출

2024년 4월 7일

QC 기준을 충족하는 최초 제출

2024년 6월 10일

처음 게시됨 (실제)

2024년 6월 12일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • S26

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

The link between participants' information data and the code will be kept confidential by the NUS research team or a trusted third party. Research data and results will only be collated in its coded format. All research data collected will be retained for a minimum of 10 years following the NUS Research Data Management Policy.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .